We are live on
!
Find out more
BRA
Bender Robert & Associates Portfolio holdings
AUM
$481M
1-Year Est. Return
35.73%
This Fund
S&P 500
This Quarter
Est. Return
+17.84%
1 Year Est. Return
+35.73%
3 Year Est. Return
+116.09%
5 Year Est. Return
+167.64%
10 Year Est. Return
+1,066.43%
AUM
$448M
AUM Growth
+$52.2M
(+13%)
Cap. Flow
-$4.91M
Cap. Flow
% of AUM
-1.1%
Top 10 Holdings %
Top 10 Hldgs %
71.99%
Holding
46
New
6
Increased
2
Reduced
33
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UroGen Pharma
URGN
|
+$333K |
| 2 |
Evolus
EOLS
|
+$257K |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
+$221K |
| 4 |
Invesco S&P 500 Equal Weight ETF
RSP
|
+$220K |
| 5 |
Pulse Biosciences
PLSE
|
+$192K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$1.48M |
| 2 |
NVIDIA
NVDA
|
+$1.08M |
| 3 |
Intuitive Surgical
ISRG
|
+$861K |
| 4 |
Mercado Libre
MELI
|
+$346K |
| 5 |
ServiceNow
NOW
|
+$290K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 43.39% |
| 2 | Consumer Discretionary | 24.18% |
| 3 | Healthcare | 16.37% |
| 4 | Communication Services | 12.41% |
| 5 | Financials | 2.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Costco
COST
$408B
| $1.43M | 0.32% |
1,445
-6
| -0.4% | -$5.96K |
|
27
JPMorgan Chase
JPM
$931B
| $745K | 0.17% |
2,570
-4
| -0.2% | -$1.02K |
|
28
AbbVie
ABBV
$463B
| $618K | 0.14% |
3,332
-32
| -1% | -$5.95K |
|
29
Abbott
ABT
$178B
| $560K | 0.12% |
4,115
+30
| +0.7% | +$3.96K |
|
30
Johnson & Johnson
JNJ
$646B
| $543K | 0.12% |
3,552
-146
| -4% | -$22.4K |
|
31
Deere & Co
DE
$183B
| $499K | 0.11% |
982
-10
| -1% | -$4.9K |
|
|
32
UroGen Pharma
URGN
$2.1B
| $475K | 0.11% |
+34,701
| New | +$333K |
|
33
Oracle
ORCL
$414B
| $440K | 0.1% |
2,014
| – | – |
|
34
Caterpillar
CAT
$362B
| $398K | 0.09% |
1,024
-40
| -4% | -$13.3K |
|
35
Merck
MRK
$358B
| $389K | 0.09% |
4,912
-20
| -0.4% | -$1.59K |
|
36
Visa
V
$700B
| $373K | 0.08% |
1,051
+42
| +4% | +$14.6K |
|
37
Gilead Sciences
GILD
$181B
| $318K | 0.07% |
2,869
-18
| -0.6% | -$1.92K |
|
38
Nucor
NUE
$57.7B
| $314K | 0.07% |
2,425
| – | – |
|
|
39
Invesco S&P 500 Equal Weight ETF
RSP
$98.9B
| $232K | 0.05% |
+1,274
| New | +$220K |
|
|
40
Evolus
EOLS
$530M
| $231K | 0.05% |
+25,070
| New | +$257K |
|
41
Duke Energy
DUK
$93B
| $218K | 0.05% |
1,848
| – | – |
|
42
Broadcom
AVGO
$1.65T
| $214K | 0.05% |
+775
| New | +$168K |
|
43
American Electric Power
AEP
$66.9B
| $213K | 0.05% |
2,050
| – | – |
|
|
44
BioCryst Pharmaceuticals
BCRX
$2.1B
| $212K | 0.05% |
+23,710
| New | +$221K |
|
45
Paychex
PAYX
$42.1B
| $212K | 0.05% |
1,455
| – | – |
|
|
46
Pulse Biosciences
PLSE
$3.91B
| $175K | 0.04% |
+11,590
| New | +$192K |
|
Similar funds
MA
WAS
SA
NC
HWMG
MAV
OMIC
SCA
Bender Robert & Associates's Q2 2025 Portfolio in Review
As of Q2 2025, Bender Robert & Associates held 46 positions worth $448M, up 13% from $396M the previous quarter. Its ten largest holdings account for 72% of the portfolio.
Bender Robert & Associates's Q2 2025 filing shows 6 new, 2 increased and 33 reduced positions. Its largest new stake was UroGen Pharma: 34,701 shares worth $475K. The largest sale was Apple, an estimated $1.48M.
By sector, the portfolio is most concentrated in Technology at 43% of assets, up from 42% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- Bender Robert & Associates's largest Q2 2025 buy was UroGen Pharma: 34,701 shares worth $475K.
- Bender Robert & Associates added most to Visa in Q2 2025, an estimated $14.6K increase.
- Bender Robert & Associates's biggest Q2 2025 reduction was Apple, cutting an estimated $1.48M.
- Bender Robert & Associates's ten largest holdings make up 72% of its $448M portfolio in Q2 2025.
- Bender Robert & Associates opened 6 new positions and closed 0 in Q2 2025.
- Bender Robert & Associates's portfolio value rose 13% quarter-over-quarter to $448M.
Based on Bender Robert & Associates's 13F filing for Q2 2025, filed 24 Jul 2025.